TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32006325
Drug: Polyethylene glycolated
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycolated exenatide injection (PB-119) at doses of 25-400 µg
Study: 616996472
Drug: Pridopidine 45
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 45 mg twice daily
Study: 616996472
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg alone
Study: 616996472
Drug: Pridopidine 90
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 90 mg single dose
Study: 32014029
Drug: Doll Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doll Therapy Intervention
Study: 35489024
Drug: Control (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (chemotherapy without bevacizumab)
Study: 33743851
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg in two 150 mg tablets twice daily)
Study: 35538754
Drug: Recombinant bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant bovine basic fibroblast growth factor gel
Study: 35538754
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Erythromycin ointment)
Study: 33238898
Drug: Continuous care
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous care (CC) by trained maternity care assistants (MCAs) during labor
Study: 33238898
Drug: Continuous care
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous care (CC)
Study: 33417699
Drug: Hierarchical Bayesian
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hierarchical Bayesian model for drug response in cancer cell lines
Study: 34492709
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise intervention (6-month, thrice weekly, moderate-vigorous intensity cycling)
Study: 33050952
Drug: Specific Emotional‐Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific Emotional‐Cognitive Therapy (SECT)
Study: 33050952
Drug: Emotion‐Focused Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion‐Focused Supportive Therapy (EFST)
Study: 32738573
Drug: Probiotic capsule
Normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsule (PC)
Study: 32738573
Drug: Control capsule
Normalized name: Azo Men Bladder Control Capsules(obs)
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control capsule (CC)
Study: 38806190
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg every other week
Study: 35574003
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin
Study: 38914294
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal ranibizumab 0.5 mg
Study: 33999371
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of parathyroid hormone (PTH) in patients with positive histology for hepatic fibrosis, steatosis, and NASH/NAFLD
Study: 36417812
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (Control group).
Study: 36116147
Drug: Acellular carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular carbohydrate sources (e.g., flour‐based whole‐grain products)
Study: 33196485
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral refeeding (IORF) - low-fat-solid diet initiated immediately after hospital admission
Study: 33196485
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral refeeding (CORF) - progressive oral diet restarted when clinical and laboratory parameters improved
Study: 33196485
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral refeeding (IORF)
Study: 32560724
Drug: Saroglitazar (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar (2 mg and 4 mg) and Pioglitazone
Study: 35385141
Drug: Cold spray
Normalized name: Butane/Isobutane/Propane Topical application Spray [COLD SPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold spray placebo
Study: 35901330
Drug: Chemotherapy (51.8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (51.8% of patients), with paclitaxel/carboplatin as the most common regimen.
Study: 35287698
Drug: Oxycodone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone + naloxone (up to 20 mg per day)
Study: 36300713
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum interleukin 2 receptor (sIL‐2R) levels
Study: 34155332
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of baclofen
Study: 33247722
Drug: Aldosterone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone infusion (0.2 and 5 ng min‐1 [L leg volume]‐1 for 10 minutes)
Study: 33247722
Drug: Aldosterone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone infusion with coinfusion of NAC (125 mg kg‐1 hour‐1 followed by 25 mg kg‐1 hour‐1)
Study: 33247722
Drug: Aldosterone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone infusion (both groups)
Study: 36235571
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g erythritol
Study: 36235571
Drug: 33.5 g
Normalized name: KETOPROFEN 33.5 g in 33.5 g TOPICAL POWDER, FOR SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33.5 g sucrose
Study: 36235571
Drug: 0.0558 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0558 g sucralose
Study: 32578066
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (hydrocortisone 500 mg before hepatic pedicle clamping, followed by 300 mg on POD 1, 200 mg on POD 2, and 100 mg on POD 3)
Study: 32458450
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of mother's milk (OPAMM) prior to gavage feeding (0.2 mL of mother's milk before each feeding)
Study: 32458450
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of mother's milk (OPAMM) prior to gavage feeding
Study: 35728781
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (500 mg azithromycin for 1 dose and 2 g cefazolin every 8 hours for up to 3 doses)
Study: 35728781
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (in class III obesity subgroup)
Study: 32277384
Drug: Financial support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial support (up to 3 weekly financial transfers of $200 each)
Study: 35536764
Drug: Febuxostat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (40 mg or 80 mg once daily)
Study: 35536764
Drug: Allopurinol (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (titrated in 100‐mg increments from 200‐400 mg or 300‐600 mg)
Study: 36148748
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 supplementation (400 IU/day)
Study: 33725800
Drug: topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical pimecrolimus
Study: 33725800
Drug: topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical tacrolimus
Study: 34114408
Drug: Zhengyuan capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhengyuan capsule (8-week regimen)
Study: 34114408
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (8-week regimen)
Study: 32539805
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) followed by L19-IL2 therapy for oligo-metastatic patients; SABR to one (symptomatic) to a maximum of 5 lesions for poly-metastatic patients.
Study: 32539805
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) combined with immunotherapy (L19-IL2).
Study: 33371058
Drug: Low-dose meropenem
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose meropenem (1g IV every 8 hours)
Study: 33371058
Drug: High-dose meropenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose meropenem (2g IV every 8 hours)
Study: 33847098
Drug: Dietary-supplemented artichoke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary-supplemented artichoke (Cynara scolymus L.) at 3g/kg in the diet of laying hens.
Study: 33847098
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 130 g/day of compound feed for laying hens without artichoke supplementation.
Study: 34076901
Drug: Ivermectin 12
Normalized name: Ivermectin 12 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 12 mg once daily for 3 days plus standard care
Study: 34060937
Drug: MET409 (farnesoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET409 (farnesoid X receptor agonist)
Study: 32958468
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy and patient education (8-week program)
Study: 36185085
Drug: Hewei Jiangni
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hewei Jiangni Decoction (HWJND) 81 g plus dummy omeprazole 20 mg daily for 8 weeks
Study: 36185085
Drug: Dummy HWJND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy HWJND granules (81 g) plus omeprazole (20 mg)
Study: 36242061
Drug: Kangyi Qiangshen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangyi Qiangshen Gong exercise prescription (KQG)
Study: 35535708
Drug: Methenamine hippurate
Normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine hippurate (1g twice daily)
Study: 32301701
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 250 mL of 0.9% normal saline containing 2 g cefuroxime sodium 30 minutes before surgery
Study: 32301701
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: cefuroxime only after returning to ward, once daily for 3 consecutive days
Study: 33359042
Drug: At-home treatment
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home treatment with 10% carbamide peroxide (2 h/day; 3 weeks)
Study: 33359042
Drug: In-office treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office treatment with 35% hydrogen peroxide (1/week; 3 weeks)
Study: 33419086
Drug: Optimizing Background
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimizing Background Infusion Mode (OBIM)
Study: 33419086
Drug: Traditional Background
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Background Infusion Mode (TBIM)
Study: 32833478
Drug: APPEAL intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APPEAL intervention (3 monthly, individually administered sessions)
Study: 33681909
Drug: Unified protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified protocol combined with mindfulness treatment
Study: 32673785
Drug: Rectal subregion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal subregion (V44-V74)
Study: 33047859
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 single doses (80-240 mg)
Study: 33047859
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 repeated doses (240 mg once weekly for 4 weeks)
Study: 33047859
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (≥120 mg)
Study: 35685052
Drug: Botulinum toxin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin‐A injections and exercise
Study: 35685052
Drug: Botulinum toxin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin‐A injections, exercise, and dry needling
Study: 34907724
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg oral daily)
Study: 33021081
Drug: Ginsenoside H
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside H dripping pill (GH) at 7.8 mg
Study: 33021081
Drug: Ginsenoside H
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside H dripping pill (GH) at 15.6 mg
Study: 33021081
Drug: Ginsenoside H
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside H dripping pill (GH) at 31.2 mg
Study: 33021081
Drug: Ginsenoside H
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside H dripping pill (GH) (multiple doses)
Study: 34069951
Drug: Intravesical administration
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical administration of liposome-encapsulated BoNT-A
Study: 34069951
Drug: Intravesical administration
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical administration of TC-3 hydrogel embedded BoNT-A
Study: 34069951
Drug: Suprapubic energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprapubic energy shock wave (ESW) after BoNT-A intravesical administration
Study: 32521325
Drug: Secukinumab treatment
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab treatment
Study: 33863635
Drug: Colistin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin plus vitamin E (α‐Tocopherol) 400 units daily
Study: 34891216
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) + CoQ10 (2 × 200 mg/day)
Study: 34891216
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) + Placebo
Study: 32040960
Drug: Triplex vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplex vaccine
Study: 32594785
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medications)
Study: 34164794
Drug: HTL0018318 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0018318 15 mg alone
Study: 34164794
Drug: HTL0018318 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0018318 25 mg alone
Study: 34164794
Drug: HTL0018318 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0018318 and donepezil combination
Study: 33372602
Drug: Adjunctive air-polishing
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive air-polishing using nozzle+erythritol powder (test group, n=21)
Study: 36308902
Drug: Diterpene Ginkgolides
Normalized name: terpene resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diterpene Ginkgolides Meglumine injection (DGMI)
Study: 33648563
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) administration for 4 consecutive days
Study: 34793406
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy (CBT)
Study: 36034802
Drug: 0.2 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/week of PEG‐rhGH
Study: 36034802
Drug: 0.14 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.14 mg/kg/week of PEG‐rhGH
Study: 35998550
Drug: Chemotherapy-Radiotherapy Interval
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy-Radiotherapy Interval (CRI) > 42 days
Study: 35998550
Drug: Chemotherapy-Radiotherapy Interval
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy-Radiotherapy Interval (CRI) < 28 or 28-42 days
Study: 33533941
Drug: Rheumatoid arthritis
Normalized name: Rheumatoid arthritis nuclear antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheumatoid arthritis (RA) cohort not receiving RA therapy
Study: 32429965
Drug: Integrated modular
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated modular teaching using different problem-based teaching methods (e.g., flipped classroom, team-based learning)
Study: 33989234
Drug: Topical nonsteroid
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nonsteroid agents (tacrolimus and anti-vascular endothelial growth factor)
Study: 37800194
Drug: Circadian Reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circadian Reinforcement Therapy (CRT)
Study: 32702169
Drug: Tropifexor 60
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor 60 µg
Study: 35642398
Drug: rock salt
Normalized name: Nivea Men Rock Salts Body Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: rock salt aerosol therapy
Study: 35642398
Drug: conventional comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional comprehensive treatment
Study: 32819390
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (ACT) consisting of 8 cycles of capecitabine plus oxaliplatin
Study: 35551928
Drug: Alcohol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (target breath alcohol content [BrAC] 80 mg/dL) and placebo cannabis
Study: 32568799
Drug: Novel technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel technique using a partial-thickness hinge punch for DMEK graft preparation
Study: 34215712
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy Program (8 sessions, 90 to 120 minutes each, over 8 weeks)
Study: 32389476
Drug: Multi‐step gradual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi‐step gradual weaning program (MG)
Study: 32389476
Drug: ADJ treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADJ treatment
Study: 33485703
Drug: Topical zinc
Normalized name: bacitracin topical zinc compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical zinc sulphate (n = 20)
Study: 34955298
Drug: Reflexology Massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology Massage with Passive Music Therapy
Study: 34704354
Drug: Atipamezole (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atipamezole (0.2 mg/kg)
Study: 34704354
Drug: Flumazenil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.1 mg/kg)
Study: 34704354
Drug: 4-Aminopyridine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-Aminopyridine (0.5 mg/kg)
Study: 34704354
Drug: Control (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (physiological saline solution at 0.1 mL/kg)
Study: 33032804
Drug: Subarachnoid morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid morphine (100 μg)
Study: 33032804
Drug: Femoral Nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral Nerve Block (BNF) with 25 mL of 0.375% ropivacaine
Study: 33032804
Drug: Femoral Nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral Nerve Block (BNF) with 25 mL of 0.25% ropivacaine
Study: 35777186
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W
Study: 33546942
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose anthocyanins (201 mg)
Study: 33546942
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose anthocyanins (47 mg)
Study: 33198608
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30)
Study: 33198608
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30)
Study: 33346782
Drug: Ticagrelor added
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor added to aspirin
Study: 33115598
Drug: CBJ with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBJ with 1000 mg of vitamin C (NC)
Study: 32524145
Drug: Ultrasound‐mediated transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound‐mediated transdermal drug delivery (group U)
Study: 32524145
Drug: Lidocaine intradermal
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine intradermal injection (group I)
Study: 38587241
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker treatment
Study: 33267853
Drug: Additional substances
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional substances daily, khat dependency, early age initiation of khat chewing
Study: 33748282
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg orally 30 min before surgery
Study: 34708399
Drug: Cannabis-based medicine
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis-based medicine (CBM)